Pouria Rahmanian-Devin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Pouria Rahmanian-Devin has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Vahid Reza Askari
Patient Safety Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
9 shared publications - Vafa Baradaran Rahimi
Patient Safety Research Center, Clinical Research Institute Mashhad University of Medical Sciences Mashhad Iran
8 shared publications - Ali Nokhodchi
School of Life Sciences, University of Sussex, Brighton BN1 9QG, UK
2 shared publications - Abouzar Shafaghi
Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication - Ali Asghar Khakshur
Mashhad University of Medical Sciences, Mashhad, Islamic Republic Of Iran
1 shared publication Ali Jebalbarezy
Department of pharmaceutical sciences in Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication
Latest Publications
- Open Access
- 10 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (3) , 286
Eugenol- and Iodoform-Loaded Lipid Liquid Crystal Dressing for Alveolar Osteitis: Formulation, In Vitro Evaluation, and a Double-Blind Randomized Clinical Trial
Purpose: This study aimed to formulate and clinically evaluate a novel lipid liquid crystal (LLC) dressing containing eugenol and iodoform, designed for sustained release, antimicrobial activity, and pain relief in alveolar osteitis (AO). Methods: Formulations with varying ratios of phosphatidylcholine (PC), sorbitan monooleate (SMO), glyceryl monooleate (GMO), and N-methyl-2-pyrrolidone (NMP) were prepared. The formulation which showed a good physicochemical stability and suitable viscosity was selected for further studies (F17, the optimized formulation). The optimized formulation was characterized for physicochemical properties and in vitro release. In a double-blind, randomized trial with 60 AO patients, the LLC-dressing was compared to Alvogyl ® for pain, analgesic use, and dressing applications over seven days. Results: The optimized formulation (F17) contained 35.25% PC, 35.25% SMO, 13.7% eugenol, and 15.8% iodoform, demonstrating an improved sustained drug release profile, appropriate viscosity, effective antibacterial activity, 100% encapsulation efficiency, and drug loading of 13.7% (eugenol) and 15.8% (iodoform). Visual Analog Scale (VAS) pain scores were comparable between LLC-dressing and Alvogyl ® at all assessed time points, with no significant differences (0 h: 8.14 ± 1.40 vs. 7.96 ± 1.02; 7 days: 0.70 ± 0.66 vs. 0.78 ± 0.60; p > 0.05). Analgesic use (5.51 ± 3.06 vs. 6.13 ± 2.87, P = 0.401) and dressing applications (2.27 ± 1.12 vs. 2.57 ± 1.20, P = 0.345) showed similar efficiency. Conclusion: The optimized LLC-dressing (F17) exhibits favorable physicochemical and in vitro characteristics and may be considered a potential alternative to Alvogyl ® for the management of AO.
- 10 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (3) , 286
Open AccessEugenol- and Iodoform-Loaded Lipid Liquid Crystal Dressing for Alveolar Osteitis: Formulation, In Vitro Evaluation, and a Double-Blind Randomized Clinical Trial
Purpose: This study aimed to formulate and clinically evaluate a novel lipid liquid crystal (LLC) dressing containing eugenol and iodoform, designed for sustained release, antimicrobial activity, and pain relief in alveolar osteitis (AO). Methods: Formulations with varying ratios of phosphatidylcholine (PC), sorbitan monooleate (SMO), glyceryl monooleate (GMO), and N-methyl-2-pyrrolidone (NMP) were prepared. The formulation which showed a good physicochemical stability and suitable viscosity was selected for further studies (F17, the optimized formulation). The optimized formulation was characterized for physicochemical properties and in vitro release. In a double-blind, randomized trial with 60 AO patients, the LLC-dressing was compared to Alvogyl ® for pain, analgesic use, and dressing applications over seven days. Results: The optimized formulation (F17) contained 35.25% PC, 35.25% SMO, 13.7% eugenol, and 15.8% iodoform, demonstrating an improved sustained drug release profile, appropriate viscosity, effective antibacterial activity, 100% encapsulation efficiency, and drug loading of 13.7% (eugenol) and 15.8% (iodoform). Visual Analog Scale (VAS) pain scores were comparable between LLC-dressing and Alvogyl ® at all assessed time points, with no significant differences (0 h: 8.14 ± 1.40 vs. 7.96 ± 1.02; 7 days: 0.70 ± 0.66 vs. 0.78 ± 0.60; p > 0.05). Analgesic use (5.51 ± 3.06 vs. 6.13 ± 2.87, P = 0.401) and dressing applications (2.27 ± 1.12 vs. 2.57 ± 1.20, P = 0.345) showed similar efficiency. Conclusion: The optimized LLC-dressing (F17) exhibits favorable physicochemical and in vitro characteristics and may be considered a potential alternative to Alvogyl ® for the management of AO.
- Open Access
- 11 September 2025
- Published by Elsevier in International Journal of Pharmaceutics: X
- Vol. 10
Overview of dendrimers as promising drug delivery systems with insight into anticancer and anti-microbial applications
- 11 September 2025
- Published by Elsevier in International Journal of Pharmaceutics: X
- Vol. 10
Open AccessOverview of dendrimers as promising drug delivery systems with insight into anticancer and anti-microbial applications
- 25 January 2025
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (1) , 57
Mechanistic insights on lycopene usage against diabetes and associated complications
Lycopene is a tetraterpene compound belonging to carotenoids that are widely present in tomatoes and similar products. It is known as a powerful anti-oxidant and a non-provitamin A carotenoid. Lycopene has been found to effectively improve diabetes mellitus and its complications, such as cardiac complications, disorders caused by oxidative stress, and liver and neurological disorders. Furthermore, free radicals have been shown to disrupt the action of insulin by changing the physical state of the target cell membrane, while carotenoids improve insulin secretion and function in blood sugar regulation by neutralizing free radicals. It, therefore, seems that targeted clinical studies are needed to investigate the therapeutic effect of lycopene against metabolic disorders induced by diabetes. This review aims to summarize information on the sources and potential uses of lycopene and the possible mechanisms involved in the reduction of the above diseases. Its protective effects, in terms of toxicity and safety, are also discussed. The literature sources used in this review were PubMed, Google Scholar, Scopus, and Web of Science databases.
- 25 January 2025
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (1) , 57
Mechanistic insights on lycopene usage against diabetes and associated complications
Lycopene is a tetraterpene compound belonging to carotenoids that are widely present in tomatoes and similar products. It is known as a powerful anti-oxidant and a non-provitamin A carotenoid. Lycopene has been found to effectively improve diabetes mellitus and its complications, such as cardiac complications, disorders caused by oxidative stress, and liver and neurological disorders. Furthermore, free radicals have been shown to disrupt the action of insulin by changing the physical state of the target cell membrane, while carotenoids improve insulin secretion and function in blood sugar regulation by neutralizing free radicals. It, therefore, seems that targeted clinical studies are needed to investigate the therapeutic effect of lycopene against metabolic disorders induced by diabetes. This review aims to summarize information on the sources and potential uses of lycopene and the possible mechanisms involved in the reduction of the above diseases. Its protective effects, in terms of toxicity and safety, are also discussed. The literature sources used in this review were PubMed, Google Scholar, Scopus, and Web of Science databases.
- Open Access
- 7 February 2024
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 23, 212-263
Niosome as a promising tool for increasing the effectiveness of anti-inflammatory compounds
Niosomes are drug delivery systems with widespread applications in pharmaceutical research and the cosmetic industry. Niosomes are vesicles of one or more bilayers made of non-ionic surfactants, cholesterol, and charge inducers. Because of their bilayer characteristics, similar to liposomes, niosomes can be loaded with lipophilic and hydrophilic cargos. Therefore, they are more stable and cheaper in preparation than liposomes. They can be classified into four categories according to their sizes and structures, namely small unilamellar vesicles (SUVs), large unilamellar vesicles (LUVs,), multilamellar vesicles (MLVs), and multivesicular vesicles (MVVs). There are many methods for niosome preparation, such as thin-film hydration, solvent injection, and heating method. The current study focuses on the preparation methods and pharmacological effects of niosomes loaded with natural and chemical anti-inflammatory compounds in kinds of literature during the past decade. We found that most research was carried out to load anti-inflammatory agents like non-steroidal anti-inflammatory drugs (NSAIDs) into niosome vesicles. The studies revealed that niosomes could improve anti-inflammatory agents' physicochemical properties, including solubility, cellular uptake, stability, encapsulation, drug release and liberation, efficiency, and oral bioavailability or topical absorption.
- 7 February 2024
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 23, 212-263
Open AccessNiosome as a promising tool for increasing the effectiveness of anti-inflammatory compounds
Niosomes are drug delivery systems with widespread applications in pharmaceutical research and the cosmetic industry. Niosomes are vesicles of one or more bilayers made of non-ionic surfactants, cholesterol, and charge inducers. Because of their bilayer characteristics, similar to liposomes, niosomes can be loaded with lipophilic and hydrophilic cargos. Therefore, they are more stable and cheaper in preparation than liposomes. They can be classified into four categories according to their sizes and structures, namely small unilamellar vesicles (SUVs), large unilamellar vesicles (LUVs,), multilamellar vesicles (MLVs), and multivesicular vesicles (MVVs). There are many methods for niosome preparation, such as thin-film hydration, solvent injection, and heating method. The current study focuses on the preparation methods and pharmacological effects of niosomes loaded with natural and chemical anti-inflammatory compounds in kinds of literature during the past decade. We found that most research was carried out to load anti-inflammatory agents like non-steroidal anti-inflammatory drugs (NSAIDs) into niosome vesicles. The studies revealed that niosomes could improve anti-inflammatory agents' physicochemical properties, including solubility, cellular uptake, stability, encapsulation, drug release and liberation, efficiency, and oral bioavailability or topical absorption.
- Open Access
- 1 December 2023
- Published by Springer Nature in Saudi Pharmaceutical Journal
- Vol. 31 (12) , 101849
Preparation and characterization of vaginal suppository of semisynthetic derivatives of ergot alkaloids cabergoline
Background: There is evidence that vaginal cabergoline can help to prevent ovarian hyperstimulation syndrome. Therefore, the vaginal suppository may be a good choice because it can be administered directly into the vagina and has no adverse effects on the stomach. In this regard we developed a cabergoline suppository as an alternative to cabergoline tablets. Design-Expert was used to determine the most suitable concentrations of PEG 6000/400, and Tween 80 to obtain a stable suppository. Specific ratios of PEG6000/400 and Tween 80 were entered as factors, and release, melting time, and hardness were evaluated as responses. In addition, the final formulation was evaluated for weight changes, pH, drug content, degradation time, deformation time, in vitro drug release, DSC analysis, infrared spectroscopy, and stability properties. Results: The suppositories were all smooth and white. They all had a weight that averaged less than 5 %. The formulations showed a pH between 6 and 6.5. The active ingredient content ranged between 79.666 ± 8.54 % and 99.67 ± 6.55 %. Suppository stiffness was between 2.74 ± 0.04 and 4.20 ± 0.03. The decomposition time of the suppositories varied between 11.25 ± 0.15 to 20.19 ± 0.08 min. The deformation time was between 26.11 ± 0.06 to 38.59 ± 0.47 min. Cabergoline content was released over 45 min from formulations of F10 (∼46 %), F2 (∼64 %), F6 (∼69 %), F4 (∼79 %), F1 (∼88 %), and F7 (∼93 %). However, other formulations released more than 95 % within 45 min. Conclusions: All variables except melting time significantly affected our responses. In vitro studies have indicated that the optimized cabergoline formula could be an excellent alternative to cabergoline oral formulations.
- 1 December 2023
- Published by Springer Nature in Saudi Pharmaceutical Journal
- Vol. 31 (12) , 101849
Open AccessPreparation and characterization of vaginal suppository of semisynthetic derivatives of ergot alkaloids cabergoline
Background: There is evidence that vaginal cabergoline can help to prevent ovarian hyperstimulation syndrome. Therefore, the vaginal suppository may be a good choice because it can be administered directly into the vagina and has no adverse effects on the stomach. In this regard we developed a cabergoline suppository as an alternative to cabergoline tablets. Design-Expert was used to determine the most suitable concentrations of PEG 6000/400, and Tween 80 to obtain a stable suppository. Specific ratios of PEG6000/400 and Tween 80 were entered as factors, and release, melting time, and hardness were evaluated as responses. In addition, the final formulation was evaluated for weight changes, pH, drug content, degradation time, deformation time, in vitro drug release, DSC analysis, infrared spectroscopy, and stability properties. Results: The suppositories were all smooth and white. They all had a weight that averaged less than 5 %. The formulations showed a pH between 6 and 6.5. The active ingredient content ranged between 79.666 ± 8.54 % and 99.67 ± 6.55 %. Suppository stiffness was between 2.74 ± 0.04 and 4.20 ± 0.03. The decomposition time of the suppositories varied between 11.25 ± 0.15 to 20.19 ± 0.08 min. The deformation time was between 26.11 ± 0.06 to 38.59 ± 0.47 min. Cabergoline content was released over 45 min from formulations of F10 (∼46 %), F2 (∼64 %), F6 (∼69 %), F4 (∼79 %), F1 (∼88 %), and F7 (∼93 %). However, other formulations released more than 95 % within 45 min. Conclusions: All variables except melting time significantly affected our responses. In vitro studies have indicated that the optimized cabergoline formula could be an excellent alternative to cabergoline oral formulations.
- Open Access
- 3 November 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 168, 115823
Preparation and characterization of solid lipid nanoparticles encapsulated noscapine and evaluation of its protective effects against imiquimod-induced psoriasis-like skin lesions
- 3 November 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 168, 115823
Open AccessPreparation and characterization of solid lipid nanoparticles encapsulated noscapine and evaluation of its protective effects against imiquimod-induced psoriasis-like skin lesions
- 7 August 2023
- Published by Taylor & Francis
- p. 189-203
Fenugreek (Trigonella foenum) and Use in Diabetes
Trigonella foenum-graecum L., commonly known as fenugreek, is an annual herbaceous plant belonging to Fabaceae. The edible parts of fenugreek are its green leaves and seeds, which have nutritional and medicinal value and have been extensively consumed as folk medicine in many countries worldwide. This chapter reviewed the promising anti-diabetic properties of fenugreek in different animal and clinical studies. Fenugreek significantly mitigated fasting blood glucose, hemoglobin A1C, HOMA index, inflammatory cytokines, oxidative stress markers, and lipid profile levels while notably propagating levels of insulin and antioxidative stress markers in animal models of Diabetes mellitus (DM), including streptozotocin, alloxan, nitrate, and high fat diet-induced DM. In addition, fenugreek showed protective effects against diabetes-induced complications, such as diabetic-induced cognitive deficits and brain damage, cardiovascular diseases, retinopathy, nephropathy, and hepatic failure. Furthermore, the ameliorating effects of fenugreek on Type 2 Diabetic patients have also been supported in several clinical trial studies.
- 7 August 2023
- Published by Taylor & Francis
- p. 189-203
Fenugreek (Trigonella foenum) and Use in Diabetes
Trigonella foenum-graecum L., commonly known as fenugreek, is an annual herbaceous plant belonging to Fabaceae. The edible parts of fenugreek are its green leaves and seeds, which have nutritional and medicinal value and have been extensively consumed as folk medicine in many countries worldwide. This chapter reviewed the promising anti-diabetic properties of fenugreek in different animal and clinical studies. Fenugreek significantly mitigated fasting blood glucose, hemoglobin A1C, HOMA index, inflammatory cytokines, oxidative stress markers, and lipid profile levels while notably propagating levels of insulin and antioxidative stress markers in animal models of Diabetes mellitus (DM), including streptozotocin, alloxan, nitrate, and high fat diet-induced DM. In addition, fenugreek showed protective effects against diabetes-induced complications, such as diabetic-induced cognitive deficits and brain damage, cardiovascular diseases, retinopathy, nephropathy, and hepatic failure. Furthermore, the ameliorating effects of fenugreek on Type 2 Diabetic patients have also been supported in several clinical trial studies.
- RetractedOpen Access
- 4 May 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-12
Carnosol Attenuates LPS-Induced Inflammation of Cardiomyoblasts by Inhibiting NF-κB: A Mechanistic in Vitro and in Silico Study
Carnosol possesses several beneficial pharmacological properties. However, its role in lipopolysaccharide (LPS) induced inflammation and cardiomyocyte cell line (H9C2) has never been investigated. Therefore, the effect of carnosol and an NF-κB inhibitor BAY 11-7082 was examined, and the underlying role of the NF-κB-dependent inflammatory pathway was analyzed as the target enzyme. Cell viability, inflammatory cytokines levels (tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and prostaglandin E2 (PGE2)), and related gene expression (TNF-α, IL-1β, IL-6, and cyclooxygenase-2 (COX-2)) were analyzed by ELISA and real-time PCR. In addition, docking studies analyzed carnosol’s molecular interactions and binding modes to NF-κB and IKK. We report that LPS caused the reduction of cell viability while enhancing both cytokines protein and mRNA levels ( , for all cases). However, the BAY 11-7082 pretreatment of the cells and carnosol increased cell viability and reduced cytokine protein and mRNA levels ( vs. LPS, for all cases). Furthermore, our in silico analyses also supported the modulation of NF-κB and IKK by carnosol. This evidence highlights the defensive effects of carnosol against sepsis-induced myocardial dysfunction and, contextually, paved the rationale for the next in vitro and in vivo studies aimed to precisely describe its mechanism(s) of action.
- 4 May 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-12
RetractedOpen AccessCarnosol Attenuates LPS-Induced Inflammation of Cardiomyoblasts by Inhibiting NF-κB: A Mechanistic in Vitro and in Silico Study
Carnosol possesses several beneficial pharmacological properties. However, its role in lipopolysaccharide (LPS) induced inflammation and cardiomyocyte cell line (H9C2) has never been investigated. Therefore, the effect of carnosol and an NF-κB inhibitor BAY 11-7082 was examined, and the underlying role of the NF-κB-dependent inflammatory pathway was analyzed as the target enzyme. Cell viability, inflammatory cytokines levels (tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and prostaglandin E2 (PGE2)), and related gene expression (TNF-α, IL-1β, IL-6, and cyclooxygenase-2 (COX-2)) were analyzed by ELISA and real-time PCR. In addition, docking studies analyzed carnosol’s molecular interactions and binding modes to NF-κB and IKK. We report that LPS caused the reduction of cell viability while enhancing both cytokines protein and mRNA levels ( , for all cases). However, the BAY 11-7082 pretreatment of the cells and carnosol increased cell viability and reduced cytokine protein and mRNA levels ( vs. LPS, for all cases). Furthermore, our in silico analyses also supported the modulation of NF-κB and IKK by carnosol. This evidence highlights the defensive effects of carnosol against sepsis-induced myocardial dysfunction and, contextually, paved the rationale for the next in vitro and in vivo studies aimed to precisely describe its mechanism(s) of action.
- 21 July 2021
- Published by Elsevier in Advances in Integrative Medicine
- Vol. 8 (4) , 312-321
Topical treatment for the prevention and relief of nipple fissure and pain in breastfeeding women: A systematic review
- 21 July 2021
- Published by Elsevier in Advances in Integrative Medicine
- Vol. 8 (4) , 312-321
Topical treatment for the prevention and relief of nipple fissure and pain in breastfeeding women: A systematic review